Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer immune markers under the microscope

NCT ID NCT07150598

Knowledge-focused Sponsor: Technische Universität Dresden Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This observational study aims to understand how the immune system and tumor markers relate to treatment response in 500 people with advanced non-small cell lung cancer. Participants will provide tumor samples before and during immunochemotherapy. The study does not test any new drug or treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better predict which lung cancer treatments work best for individual patients.
What could go wrong
This is an early observational study, not a treatment trial. It may not lead to immediate changes in patient care, and results may not apply to all lung cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be adult patients (≥18 years) with histologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC) who are initiating or receiving standard-of-care immunochemotherapy. Eligible participants must be able to provide tumor biopsy material at predefined time points (baseline, 6 weeks after treatment start, and/or at progression or therapy line change). Both male and female patients will be included.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For all: * Written informed consent of the patient * Consent of participation in the national Network for Genomic Medicine in Lung Cancer (nNGM) * Advanced lung cancer with non-curative treatment option (NSCLC) * No targetable driver mutation detected, defined as no targetable drive mutation in ALK, EGFR, BRAF, HER2, MET, NTRK, RET, ROS1 * PD-L1 expression on tumor cells (TPS \< 50%) Cohort A: * Previously untreated NSCLC without curative treatment options * Sufficient pre-treatment tumor material available for the planned analyses or consenting and able to undergo additional pretreatment biopsy * Scheduled to undergo immune(chemo)therapy * Willing and able to undergo re-biopsy 6 weeks after start of immune(chemo)therapy Cohort B: * Any line of progression after firstline immune(chemo)therapy * Sufficient tumor material obtained after progression on most recent line of treatment available or willing and able to undergo re-biopsy prior to next line treatment Exclusion Criteria: * Any condition representing an unjustified risk for obtaining an additional biopsy sample (if needed) in the view of the investigator * Incapability of understanding the purpose and possible consequences of the trial * Substance abuse, medical, psychological or social conditions that may interfere with the subject's cooperation with the requirements of the trial or evaluation of the study results

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (advanced non-small cell lung cancer) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (advanced non-small cell lung cancer) NSCLC (non-small cell lung cancer) NSCLC stage IIIB~iv

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Universitätsklinikum Carl Gustav Carus

    Dresden, Saxony, 01307, Germany

  • Universitätsklinikum Köln, Centrum für Integrierte Onkologie (CIO) Köln

    Cologne, North Rhine-Westphalia, 50937, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.